Candriam SCA’s Lexicon Pharmaceuticals LXRX Stock Holding History

Candriam SCA’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-509,000	Closed	-$3.38M	–	818
2018 Q4	$3.38M	Hold	509,000	–	–	0.05%	356
2018 Q3	$5.43M	Buy	509,000 +137,000	+37%	+$1.57M	0.07%	297
2018 Q2	$4.46M	Buy	372,000 +104,000	+39%	+$1.06M	0.07%	317
2018 Q1	$2.3M	Hold	268,000	–	–	0.04%	450
2017 Q4	$2.65M	Sell	268,000 -25,000	-9%	-$260K	0.05%	400
2017 Q3	$3.6M	Hold	293,000	–	–	0.06%	336
2017 Q2	$4.82M	Buy	293,000 +33,000	+13%	+$511K	0.09%	269
2017 Q1	$3.73M	Buy	260,000 +65,000	+33%	+$964K	0.07%	316
2016 Q4	$2.7M	Hold	195,000	–	–	0.06%	312
2016 Q3	$3.52M	Buy	195,000 +67,000	+52%	+$1.08M	0.08%	255
2016 Q2	$1.84M	Sell	128,000 -25,000	-16%	-$339K	0.05%	327
2016 Q1	$1.82M	Sell	153,000 -12,000	-7%	-$126K	0.05%	336
2015 Q4	$2.2M	Buy	+165,000	New	+$2.03M	0.06%	283
2015 Q2	–	Sell	-81,429	Closed	-$538K	–	652
2015 Q1	$538K	Hold	81,429	–	–	0.01%	535
2014 Q4	$519K	Buy	+81,429	New	+$656K	0.01%	517

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Candriam SCA's LXRX Position: Q1 2019 in Review

Candriam SCA sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2019, closing a stake of 509,000 shares — an estimated $3.38M sold.

Candriam SCA first reported a position in LXRX in Q4 2014 and held it in 15 quarters. The position peaked at $5.43M in Q3 2018. 121 funds tracked by Wall St. Rank hold LXRX as of Q1 2019.

Candriam SCA reported no remaining Lexicon Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Candriam SCA sold 509,000 Lexicon Pharmaceuticals shares in Q1 2019, an estimated $3.38M.
Candriam SCA first reported a position in Lexicon Pharmaceuticals in Q4 2014 and held it in 15 quarters.
Candriam SCA's Lexicon Pharmaceuticals position peaked at $5.43M in Q3 2018.
121 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2019.

Based on Candriam SCA's 13F filing for Q1 2019, filed 2 May 2019.